These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal. Mannucci C; Navarra M; Pieratti A; Russo GA; Caputi AP; Calapai G Nicotine Tob Res; 2011 Apr; 13(4):239-47. PubMed ID: 21324836 [TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid modulation of male rat sexual behavior. Gorzalka BB; Morrish AC; Hill MN Psychopharmacology (Berl); 2008 Jul; 198(4):479-86. PubMed ID: 17694389 [TBL] [Abstract][Full Text] [Related]
12. A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine. Manna SS; Umathe SN Eur J Pharmacol; 2012 Jun; 685(1-3):81-90. PubMed ID: 22542657 [TBL] [Abstract][Full Text] [Related]
13. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. Khasabova IA; Khasabov S; Paz J; Harding-Rose C; Simone DA; Seybold VS J Neurosci; 2012 May; 32(20):7091-101. PubMed ID: 22593077 [TBL] [Abstract][Full Text] [Related]
14. Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys. Schindler CW; Scherma M; Redhi GH; Vadivel SK; Makriyannis A; Goldberg SR; Justinova Z Psychopharmacology (Berl); 2016 May; 233(10):1867-77. PubMed ID: 26803499 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of fatty acid amide hydrolase by URB597 attenuates the anxiolytic-like effect of acetaminophen in the mouse elevated plus-maze test. Zaitone SA; El-Wakeil AF; Abou-El-Ela SH Behav Pharmacol; 2012 Aug; 23(4):417-25. PubMed ID: 22750843 [TBL] [Abstract][Full Text] [Related]
16. Acute effects of endocannabinoid anandamide and CB1 receptor antagonist, AM251 in the regulation of thyrotropin secretion. da Veiga MA; Fonseca Bloise F; Costa-E-Sousa RH; Souza LL; Almeida NA; Oliveira KJ; Pazos-Moura CC J Endocrinol; 2008 Nov; 199(2):235-42. PubMed ID: 18755884 [TBL] [Abstract][Full Text] [Related]
17. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. Desroches J; Charron S; Bouchard JF; Beaulieu P Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808 [TBL] [Abstract][Full Text] [Related]
18. Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Vlachou S; Nomikos GG; Panagis G Psychopharmacology (Berl); 2006 Oct; 188(3):293-305. PubMed ID: 16953388 [TBL] [Abstract][Full Text] [Related]
19. Role of endocannabinoid signalling in the dorsolateral periaqueductal grey in the modulation of distinct panic-like responses. Batista LA; Bastos JR; Moreira FA J Psychopharmacol; 2015 Mar; 29(3):335-43. PubMed ID: 25601395 [TBL] [Abstract][Full Text] [Related]
20. Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors. Sartim AG; Guimarães FS; Joca SR Behav Brain Res; 2016 Apr; 303():218-27. PubMed ID: 26801828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]